Trastuzumab deruxtecan NEW
| Price | $728 | $1480 | $1960 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: Trastuzumab deruxtecan | CAS No.: 1826843-81-5 |
| Purity: SEC-HPLC:98.49% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | Trastuzumab deruxtecan |
| Description | Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer. |
| In vitro | METHODS: HER2-positive KPL-4 cells were treated with Trastuzumab deruxtecan (T-DXd) (1 pM-10 nM, 5 days) and cell viability was calculated. RESULTS: Trastuzumab deruxtecan can inhibit the growth of HER2-positive KPL-4 cells with an IC50 value of 109.7 pM. [2] METHODS: Trastuzumab deruxtecan (10 nM, 5 days) was used to treat co-cultured HER2-positive KPL-4 cells and HER2-negative MDA-MB-468 cells, and the number of viable cells was measured to determine whether it induced bystander killing. RESULTS: Trastuzumab deruxtecan killed both KPL-4 and MDA-MB-468 cells. [2] |
| In vivo | METHODS: Trastuzumab deruxtecan (T-DXd) (10 mg/kg, intravenous injection) was used to treat EMT6-hHER2 tumor-bearing mice, and the changes in tumors in the mice were observed. RESULTS: Trastuzumab deruxtecan significantly inhibited tumor growth in EMT6-hHER2 tumor-bearing mice 18 days after treatment. [1] |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Keywords | Trastuzumab deruxtecan |
| Inhibitors Related | Disitamab vedotin | Trastuzumab emtansine | Cantuzumab ravtansine | Datopotamab deruxtecan | Glembatumumab vedotin | Labetuzumab govitecan | Polatuzumab vedotin | Cantuzumab mertansine | Brentuximab vedotin | Sacituzumab govitecan | Zilovertamab vedotin | Loncastuximab tesirine |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2150.00/10mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $3480.00/10mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/1G |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-01-10 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY